Jonathan G. Drachman - Aug 3, 2021 Form 4 Insider Report for Neoleukin Therapeutics, Inc. (NLTX)

Role
President and CEO, Director
Signature
/s/ Kris McGrew, Attorney-in-Fact for Jonathan G. Drachman
Stock symbol
NLTX
Transactions as of
Aug 3, 2021
Transactions value $
$0
Form type
4
Date filed
8/5/2021, 04:12 PM
Previous filing
Jun 14, 2021
Next filing
Aug 26, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NLTX Stock Option (Right to Buy) Award $0 +400K $0.00 400K Aug 3, 2021 Common Stock 400K $6.80 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 1/4 of the total shares on August 3, 2022, and then 1/48 of the total shares will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.